GlassScriptPhysician profile
Nathaniel Reisinger
NPI 1881960938
$2,244.61
in general payments reported to CMS, 2019-2025
9 companies · $1,611 in 2025
The $1,611 reported for 2025 was more than what 87% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2022: $194 · 2023: $203 · 2024: $101 · 2025: $1,611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $908 · Travel and Lodging: $781 · Consulting Fee: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $908.38 |
| Travel and Lodging | $781.33 |
| Consulting Fee | $225.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $1,120.13 | 2025 | |
| Vifor Pharma, INC. | $379.23 | 2022-2024 | Veltassa |
| Radiometer America, INC | $225.00 | 2025 | |
| Amgen INC. | $201.61 | 2019-2025 | Tavneos, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $124.66 | 2025 | Farxiga |
| Glaxosmithkline, LLC. | $118.34 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $45.41 | 2019-2025 | Jynarque, Voyxact |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.74 | 2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $14.49 | 2025 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Reisinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.